Adjuvant therapy

Recent Results in Cancer Research

Volumn 171, Issue , 2009, Pages 141-153

  Wick, Wolfgang ^a   Weller, Michael ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRADYKININ DERIVATIVE; CARBOPLATIN; CARMUSTINE; CILENGITIDE; CISPLATIN; CYTARABINE; DLL 520; ENZASTAURIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; IMATINIB; LABRADIMIL; LOMUSTINE; NIMUSTINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCARBAZINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; TAMOXIFEN; TEMOZOLOMIDE; TENIPOSIDE; THALIDOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GENE THERAPY; CANCER RECURRENCE; DIARRHEA; DRUG HYPERSENSITIVITY; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; LUNG EDEMA; LUNG FIBROSIS; LYMPHOCYTOPENIA; MEDULLOBLASTOMA; MULTIMODALITY CANCER THERAPY; NAUSEA; NEPHROTOXICITY; OLIGODENDROGLIOMA; OTOTOXICITY; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TREATMENT INDICATION; ALTERNATIVE MEDICINE; ASTROCYTOMA; BRAIN TUMOR; GENE THERAPY;

ASTROCYTOMA; BRAIN NEOPLASMS; COMPLEMENTARY THERAPIES; GENE THERAPY; GLIOMA; HUMANS; OLIGODENDROGLIOMA;

EID: 67449091149     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-31206-2_8     Document Type: Review

References (54)

1. Alberts DS, Dorr RT (1998) New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. The Oncologist 3:15-34
2. Balmaceda C, Heller G, Rosenblum M, Diez B, Villablanca JG, Kellie S, Maher P, Vlamis V, Walker RW, Leibel S, Finlay JL (1996) Chemotherapy without irradiation - a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol 14:2908-2915
3. Baranzelli MC, Patte C, Bouffet E, Couanet D, Habrand JL, Portas M, Lejars O, Lutz P, Le Gall E, Kalifa C (1997) Nonmetastatic intracranial germinoma: The experience of the French Society of Pediatric Oncology. Cancer 80:1792-1797 (Pubitemid 27475938)
4. Brandes AA, Rigon A, Zampieri P, Ermani M, Carollo C, Altavilla G, et al. (1998) Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme. A phase II study. Cancer 82: 355-361
5. Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amistà P, et al. (1999a) Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: A phase II study. J Clin Oncol 17: 645-650
6. Brandes AA, Palmisano V, Monfardini S (1999b) Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat Rev 25:3-12
7. Brightman MW, Reese TS (1969) Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40:648-677
8. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, et al. (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12(10):2013-2021
9. Cairncross G, Swinnen L, Bayer R, Rosenfeld S, Salzman D, Paleologos N, et al. (2000) Myeloablative chemotherapy for recurrent aggressive oligo dendroglioma. Neurooncol 2:114-119
10. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714
11. Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulinlike growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200-207
12. Chiocca EA, Abbed KM, Tatter S, et al. (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10:958-966
13. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, et al. (1996) Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2:619-622
14. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
15. Fine HA, Kim L, Royce C, et al. (2005) Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. Proc. ASCO 1504
16. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857
17. Glioma Meta-analysis Trialists (GMT) Group (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018
18. Gnekow AK, Kortmann RD, Pietsch T, Emser A (2004) Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristine chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy - report from the multicenter treatment study for children and adolescents with a low grade glioma - HIT-LGG 1996 - of the Society of Pediatric Oncology and Hematology (GPOH). Klin Pädiatr 216:331-342
19. Goekjian PG, Jirousek MR (2001) Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10:2117-2214
20. Hegi M, Diserens A, Gorlia T, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
21. Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB, et al. (2002) Gliomatosis cerebri. Molecular pathology and clinical course. Ann Neurol 52:390-399
22. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann R-D, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Sommer C, Bamberg M, Reifenberger G, Weller M (2006) UKT-03 phase II trial of CCNU plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 24:4412-4417
23. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB (1990) Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321-324
24. Liston P, Fong WG, Korneluk RG (2003) The inhibitors of apoptosis: There is more to life than Bcl-2. Oncogene 22:8568-8580
25. Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E (1996) Phase II Study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol 7(2):205-207
26. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024
27. Neuro-Oncology Working Group (NOA) of the German Cancer Society (2003) Neuro-Oncology Working Group (NOA)-01 trial of ACNU/VM26 versus ACNU/Ara-C chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21:3276-3284
28. Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, et al. (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86:747-754
29. Prados MD, Schold SC JR SC, Fine HA, Jaeckle K, Hochberg F, Mechtler L, et al. (2003) A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neurooncol 5:96-103
30. Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 112389-112401
31. Rodriguez LA, Prados M, Silver P, Levin VA (1989) Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64:2420-2423
32. Rubin LL, Staddon JM (1999) The cell biology of the blood-brain barrier. Annu Rev Neurosci 22:11-28
33. Salvesen GS, Duckett CS (2002) IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3:401-410
34. Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J, et al. (2004) Initial chemotherapy in gliomatosis cerebri. Neurology 63:270-275
35. Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M (2006) PCV chemotherapy for recurrent glioblastoma. Neurology 66:587-589
36. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 352:987-996
37. Stupp R, Goldbrunner R, Neyns B, Schlegel U, Clement P, Grabenbauer GG, Hegi ME, Nippgen J, Picard M, Weller M (2007) Phase I/IIa Trial of Cilengitide (EMD121974) and Temozolomide With Concomitant Radiotherapy, Followed by Temozolomide and Cilengitide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. ASCO 2007
38. Takakura K, Abe H, Tanaka R, Kitamura K, Miwa T, Takeuchi K, et al. (1986) Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 64:53-57
39. Triebels VH, Taphoorn MJ, Brandes AA, Menten J, Frenay M, Tosoni A, et al. (2004) Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology 63:904-906
40. van den Bent M, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma- Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24;2715-2722
41. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259
42. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, et al. (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333-343
43. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, et al. (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329
44. Weiler M, Bähr O, Hohlweg U, et al. (2006) BCL-xL: Time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. Cell Death and Differ 13:1156-1169
45. Weller M, Rieger J, Grimmel C, et al. (1998) Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. Int J Cancer 79:640-644
46. Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A; German Glioma Network (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomaker? Clin Cancer Res 13(23):6933-6937
47. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. (2003) A phase 3 trial of local chemotherapy with biodegradable wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol 5:79-88
48. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E; On behalf of the Executive Committee of the Gliadel Study Group (2006) Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269-275
49. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick.W (2007) Efficacy and tolerability of Temozolomide in an one week on/one week off regimen in patients with recurrent glioma. J Clin Oncol (in press)
50. Wolff JE, Finlay JL (2004) High-dose chemotherapy in childhood brain tumors. Onkologie 27:239-245
51. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL (1998) Malignant peripheral nerve sheath tumor: Analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42:351-360
52. Yung WKA, Prados MD, Yaga-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. for the Temodal Brain Tumor Group (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762-2771
53. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593
54. Zander T, Nettekoven W, Kraus JA, Pels H, Ko YD, Vetter H, Klockgether T, Schlegel U (2002) Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma. J Neurol 249:1055-1057